10월 12일 11:00

Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)

Mundipharma today announced completion of patient enrolment for the ongoing, global Phase III ReSPECT trial evaluating REZZAYO® (rezafungin). The ReSPECT trial is a global, randomised, double-blind, controlled, pivotal Phase 3 trial of rezafungin ...

10월 12일 11:00

문디파마, 레자요®에 대한 제3상 ReSPECT 임상 시험에서 환자 등록 완료 발표

문디파마(Mundipharma)가 레자요®(REZZAYO®)(레자펀진)를 평가하는 진행 중인 글로벌 3상 ReSPECT 시험에 대한 환자 등록이 완료됐다고 발표했다. ReSPECT 시험은 동종 혈액 및 골수 이식을 받는 시험대상자에서 칸디다, 아스페르길루스 및 뉴모자자충으로 인한 침습...

2021년 1월 27일 10:58

Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis

Mundipharma and Cidara Therapeutics today announced that the European Commission (EC) has now adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to rez...

2021년 1월 19일 17:40

Julie Dehaene-Puype and Erik Nordkamp appointed as new regional Commercial Officers for Mundipharma

FOR MEDICAL BUSINESS/INDUSTRY TRADE MEDIA ONLY The Mundipharma network of independently associated companies today announced two new appointments to their Executive Committee - Julie Dehaene-Puype as Chief Commercial Officer, Europe and Erik Nordk...

 전체 기업